Stącel Tomasz, Antończyk Remigiusz, Latos Magdalena, Nęcki Mirosław, Przybyłowski Piotr, Zembala Marian, Ochman Marek, Urlik Maciej
Silesian Center for Heart Diseases, Zabrze, Poland.
Silesian Center for Heart Diseases, Zabrze, Poland; Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Medical University of Silesia, Katowice, Poland.
Transplant Proc. 2020 Sep;52(7):2113-2117. doi: 10.1016/j.transproceed.2020.02.113. Epub 2020 Apr 2.
Primary pulmonary hypertension can lead to hypertrophy of the right ventricle and ultimately to its insufficiency. Lung transplantation remains the only viable treatment for patients with certain forms of this disease. Usage of extracorporeal membrane oxygenation in veno-arterial form (VA-ECMO) after transplantation is both protective for left ventricle (enables adaptation to increased blood flow) and right ventricle (provides time to return to appropriate dimensions and in some cases to correct tricuspid regurgitaion).
The case study describes 4 patients who were treated with VA-ECMO as a perioperative support. Three patients were diagnosed with idiopathic form of precapillary primary pulmonary hypertension. A fourth patient was a 49-year old woman diagnosed with hypoplastic pulmonary veins representing the postcapillary form of pulmonary hypertension. In all of the cases, VA-ECMO was introduced during the surgery (femoral vein/internal jugular vein and femoral artery) and maintained for several days after the transplantation. Regular echocardiographic and biochemical assessment in postoperative course revealed that cardiac function improved during and after such treatment among all patients. They were successfully weaned off ECMO and finally surgically explanted without any local complications. One patient was treated with awake ECMO protocol.
VA-ECMO was proved to be a useful tool during the transplantation and postoperative period. It helps to restore proper cardiac function, as well as prevent adverse effects of aforementioned pathologic changes of a heart.
原发性肺动脉高压可导致右心室肥厚并最终导致右心室功能不全。肺移植仍然是患有某些形式的这种疾病的患者唯一可行的治疗方法。移植后使用静脉 - 动脉形式的体外膜肺氧合(VA - ECMO)对左心室具有保护作用(使其适应增加的血流量),对右心室也有保护作用(提供时间使其恢复到适当尺寸,在某些情况下纠正三尖瓣反流)。
该病例研究描述了4例接受VA - ECMO作为围手术期支持治疗的患者。3例患者被诊断为毛细血管前性原发性肺动脉高压的特发性形式。第四例患者是一名49岁女性,被诊断为肺静脉发育不全,代表毛细血管后性肺动脉高压形式。在所有病例中,VA - ECMO在手术期间(股静脉/颈内静脉和股动脉)引入,并在移植后维持数天。术后常规超声心动图和生化评估显示,所有患者在此类治疗期间及之后心功能均有改善。他们成功撤离ECMO,最终手术取出,无任何局部并发症。1例患者采用清醒ECMO方案治疗。
VA - ECMO被证明是移植及术后期间的一种有用工具。它有助于恢复正常心功能,并预防上述心脏病理变化的不良影响。